Drug Profile
CC 1088
Alternative Names: CC 801; CDC 801Latest Information Update: 04 Dec 2019
Price :
$50
*
At a glance
- Originator Celgene Corporation
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Crohn's disease; Myelodysplastic syndromes
Most Recent Events
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol Myers Squibb
- 16 Aug 2004 Discontinued - Phase-II for Myelodysplastic syndromes in USA (unspecified route)
- 21 Feb 2003 Discontinued - Phase-I for Crohn's disease in United Kingdom (unspecified route)